Gilead Sciences

Quiet times return for biopharma takeouts
Quiet times return for biopharma takeouts
EP Vantage
M&A
Alexion
Amgen
AstraZeneca
Biogen
Five Prime Therapeutics
Gilead Sciences
GW Pharma
Horizon Therapeutics
Immunomedics
Jazz Pharmaceutical
Kymab
Merck
Pandion
Sanofi
Viela Bio
Flag link:
Gilead stops Veklury study, citing enrollment challenges, changing treatment
Gilead stops Veklury study, citing enrollment challenges, changing treatment
BioPharma Dive
Gilead Sciences
COVID-19
remdesivir
Veklury
clinical trials
Flag link:
India axes exports of Gilead Sciences' remdesivir, plots boost to local production as COVID cases mount: reports
India axes exports of Gilead Sciences' remdesivir, plots boost to local production as COVID cases mount: reports
Fierce Pharma
India
drug manufacturing
Gilead Sciences
remdesivir
COVID-19
Flag link:
Gilead scores US approval for breast cancer drug that wowed ESMO
Gilead scores US approval for breast cancer drug that wowed ESMO
Pharmaforum
Gilead Sciences
Trodelvy
FDA
ESMO
triple negative breast cancer
Flag link:
CEO Dan O'Day, tasked with boosting Gilead's oncology presence, scores $19M for a year focused on COVID
CEO Dan O'Day, tasked with boosting Gilead's oncology presence, scores $19M for a year focused on COVID
Fierce Pharma
Gilead Sciences
Daniel O'Day
executive pay
Pharma CEOs
Flag link:
Pharma Gilead has sole rights to COVID-19 blockbuster Veklury, GAO concludes
Pharma Gilead has sole rights to COVID-19 blockbuster Veklury, GAO concludes
Fierce Pharma
Gilead Sciences
remdesivir
Veklury
GAO
COVID-19
Flag link:
Biotech pioneer and startup investor John Martin, who built Gilead into a powerhouse player, has died
Biotech pioneer and startup investor John Martin, who built Gilead into a powerhouse player, has died
Endpoints
Gilead Sciences
John Martin
Pharma CEOs
Flag link:
How Gilead's and Merck's Surprise Partnership Will Shake Up the HIV Market
How Gilead's and Merck's Surprise Partnership Will Shake Up the HIV Market
Motley Fool
Gilead Sciences
Merck
HIV
drug development
Flag link:
Gilead, Novo Nordisk push NASH cocktail deeper into the clinic
Gilead, Novo Nordisk push NASH cocktail deeper into the clinic
Fierce Biotech
Gilead Sciences
Novo Nordisk
NASH
R&D
Flag link:
Gilead, Merck combine forces in HIV
Gilead, Merck combine forces in HIV
BioPharma Dive
Gilead Sciences
Merck
HIV
Flag link:
Aelix posts HIV vaccine data ahead of Gilead combo readout
Aelix posts HIV vaccine data ahead of Gilead combo readout
Fierce Biotech
Aelix Therapeutics
HIV
vaccines
Gilead Sciences
Flag link:
Gilead's Biktarvy build its case for long-term use with 4-year data showing lasting HIV suppression
Gilead's Biktarvy build its case for long-term use with 4-year data showing lasting HIV suppression
Endpoints
Gilead Sciences
Biktarvy
HIV
Flag link:
Amid back office consolidation, Gilead axes 179 jobs in California
Amid back office consolidation, Gilead axes 179 jobs in California
Endpoints
Gilead Sciences
California
North Carolina
RTP
layoffs
Flag link:
While Life Sciences Industry Remains Strong, Some Big Names Face Layoffs
While Life Sciences Industry Remains Strong, Some Big Names Face Layoffs
BioSpace
COVID-19
pandemic
layoffs
Gilead Sciences
Amgen
GSK
Sanofi
Viatris
Flag link:
Gilead's $5B Galapagos black hole widens as pair toss out phase 3 asset after flop
Gilead's $5B Galapagos black hole widens as pair toss out phase 3 asset after flop
Fierce Biotech
Gilead Sciences
Galapagos
IPF
ziritaxestat
Flag link:
Watch out, Gilead: TG Therapeutics wins FDA nod for potentially safer Zydelig rivalrnings season continues to show COVID-19 uncertainty
Watch out, Gilead: TG Therapeutics wins FDA nod for potentially safer Zydelig rivalrnings season continues to show COVID-19 uncertainty
Fierce Pharma
TG Therapeutics
FDA
Ukoniq
umbralisib
follicular lymphoma
marginal zone lymphoma
Gilead Sciences
Flag link:
'Can't say no': Kite Pharma taps Frank Neumann as new head of clinical development
'Can't say no': Kite Pharma taps Frank Neumann as new head of clinical development
Endpoints
Kite Pharma
Gilead Sciences
clinical development
Flag link:
Veklury rescues Gilead from COVID doldrums in Q4
Veklury rescues Gilead from COVID doldrums in Q4
Pharmaforum
Gilead Sciences
Veklury
earnings
Flag link:
Gilead partners with a cancer biotech, seeking to develop an HIV immunotherapy
Gilead partners with a cancer biotech, seeking to develop an HIV immunotherapy
BioPharma Dive
Gilead Sciences
HIV
Gritstone Oncology
drug development
Flag link:
Remdesivir, Given to Half of Hospitalized Covid Patients in U.S., Is Big Win for Gilead — Boosted by Taxpayers
Remdesivir, Given to Half of Hospitalized Covid Patients in U.S., Is Big Win for Gilead — Boosted by Taxpayers
KHN
Gilead Sciences
remdesivir
COVID-19
Flag link:

Pages